TrialBMC cardiovascular disorders2022

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.

Ashutosh Wechalekar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.